Back to search

United Kingdom· GB-APID-45157511000001105

Rivaroxaban 10mg tablets

A rivaroxaban product containing rivaroxaban, registered in United Kingdom by Krka UK Ltd. The same ATC class is registered in 15 of our 19 countries.

ATC B01AF01

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedRivaroxaban 10mg tabletsATCB01AF01REGISTER NO.GB-APID-4515751100000…PACKS LISTED2CHECKEDSeptember 13, 2026

Where it is registered

Rivaroxaban is registered in 15 of 19 countries.

Countries holding a registration under ATC B01AF01 (rivaroxaban), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 9 of them publish a price we can compare per daily dose

Rivaroxaban · ATC B01AF01

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rivaroxaban costs, country by country.

Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.67 in France to $5.20 in United States — a ×7.7 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Rivaroxaban · price per daily dose (20 mg)

USD · FX 28 Sept 2026

  • US United States$5.20 (acquisition cost)
  • CH Switzerland$2.66
  • IT Italy$1.08
  • FR France$0.67
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Rivaroxaban
Manufacturer
Krka UK Ltd
Country
United Kingdom (GB)
ATC code
B01AF01
ATC class
Rivaroxaban
Defined daily dose
20 mg, O
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 2

  • gtin
    3838989769291
  • gtin
    3838989769307

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

391 interactions on record for rivaroxaban.

Graded by severity as the source publishes them — 134 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Rivaroxaban · interactions on record

391 records

  • 134 severe
  • 213 moderate
  • 2 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe

42 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rivaroxaban in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rivaroxaban products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Rivahib, Rivaroksaban Grindeks
  • Belgium · Rivaroxaban, Rivaroxaban  Eg
  • Bulgaria · Xaboplax Sandoz Pharmaceuticals D.D, Виатрикс
  • Cyprus · Enkia, Naxat
  • Czechia · Axaltra, Bevimlar
  • Germany · Elmardya, Rivadia
  • Denmark · Blomensy, Dovequa
  • Estonia · Enkia, Kardatuxan
  • Spain · Blomensy, Elmardya
  • Finland · Blomensy, Dovequa
  • France · Elmardya, Rivaroxaban Almus
  • Greece · Blomensy, Cinstel
  • Croatia · Aban, Bevimlar
  • Hungary · Dovequa, Evoxyr
  • Ireland · Rivaroxaban Ascend, Rivaroxaban Azure
  • Iceland · Agublon, Barsovi
  • Italy · Ellebax, Indifaxa
  • Liechtenstein · Rivaroxaban Accord, Rivaroxaban Viatris
  • Lithuania · Enkia, Kardatuxan
  • Luxembourg · Rivaroxaban Eg, Rivaroxaban Eg (Eurogenerics) Nv
  • Latvia · Kardatuxan, Mibrex
  • Malta · Enkia, Naxat
  • Netherlands · Blomensy, Rivaroksaban Grindeks
  • Norway · Dovequa, Rivaroxaban Accord
  • Poland · Axaltra, Bevimlar
  • Portugal · Closderive, Enkia
  • Romania · Closderive, Enkia
  • Sweden · Bevimlar, Blomensy
  • Slovenia · Dovequa, Ribas
  • Slovakia · Assubex, Bevimlar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/1c4b1dd1-3e00-45ef-8f2e-ae228129977a
GET /v1/drugs/1c4b1dd1-3e00-45ef-8f2e-ae228129977a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "45157511000001105",
  "desc": "Rivaroxaban 10mg tablets (Krka UK Ltd)",
  "form": "Oral tablet",
  "vpid": "14254711000001104",
  "source": "dmd",
  "vtm_id": "777455008",
  "strength": "10 mg",
  "substance": "Rivaroxaban",
  "ingredient": "Rivaroxaban",
  "supplier_code": "41342011000001109"
}

See everything about rivaroxaban.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.